-- ニュース(ASX:NWS)の第3四半期決算は「堅調」で、力強い成長を示したと、投資会社ジャーデンは金曜日のレポートで述べた。 金利・税金・減価償却費・償却費控除前利益(EBITDA)は前年同期比18%増となり、ジャーデンの予想を2%上回った。ダウ・ジョーンズ関連事業が好業績の主要因となった。調整後税引後純利益は前年同期比20%増となった。 ジャーデンによると、同社の書籍出版部門は紙媒体および電子書籍の売上増加の恩恵を受けた。一方、最も規模の小さいニュース・メディア部門は、カリフォルニア・ポストの創刊の影響で予想を大きく下回った。 ジャーデンはニュースの投資判断を「オーバーウェイト」に据え置き、目標株価を46.30豪ドルとした。 ニュースの株価は、金曜日の取引で4%上昇した。
Related Articles
Regis Resources Says Morgan Stanley, Units Acquire 5.87% Stake
Regis Resources (ASX:RRL) said Morgan Stanley and its subsidiaries became a substantial holder of the firm after acquiring 44.4 million shares, or a 5.87% stake, on Tuesday, according to a Friday Australian bourse filing.
Jumpcan Pharma's Jianwei Xiaoshi Oral Liquid Added to China's Centralized Procurement Program
Hubei Jumpcan Pharmaceutical's (SHA:600566) Jianwei Xiaoshi Oral Liquid was selected for the National Chinese Patent Medicine's centralized procurement, according to a Friday disclosure to the Shanghai bourse.The drug is used to treat food stagnation and indigestion.During the procurement period, medical institutions will prioritize the use of the selected products, the pharmaceutical company said.
Tabcorp Likely Faces Remediation Costs from Austrac Probe, But Sell-Off Overdone, Jarden Says
Tabcorp Holdings (ASX:TAH) likely faces remediation costs in a new regulatory enforcement investigation, and repeat offender status is also a risk, but neither of those factors justifies the magnitude of the sell-off in the company's stock, Jarden said in a Thursday note.The Australian Transaction Reports and Analysis Center (AUSTRAC) is investigating the company's compliance with anti-money laundering and counter-terrorism financing obligations, citing concerns about its ability to identify and mitigate risks.Jarden noted there is no certainty of a financial penalty as the regulator's disclosure stated that all outcomes are on the table, while previous cases show that a zero-penalty result is possible when the regulator is satisfied with cooperation.AUSTRAC's previous gambling sector penalties have ranged from zero to AU$450 million, the equity research firm said, adding that it views top-line implications for Tabcorp as limited.The company's shares fell sharply after the disclosure of the probe, and at those levels, "the stock appears to be factoring a cost impost well in excess of what the precedent set supports," Jarden said.It maintained an overweight rating on Tabcorp with a target price of AU$1.05, saying it will revisit those assessments if Austrac files civil penalty proceedings or Tabcorp takes on provisions related to the case.The company's shares fell 13% in recent Friday trade.